Introduction
Graves' orbitopathy (GO) is the major and most frequent extrathyroidal manifestation of Graves' disease [1] . Its prevalence in patients with Graves' hyperthyroidism of recent onset seems to be declining in recent years [2] . However, moderate-to-severe forms requiring aggressive treatment,
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although rarer than in the past [3] , are still observed, with an approximate incidence of 16/million per year [4] . Progression to severe forms may, in some instances, be triggered by radioiodine treatment for Graves' hyperthyroidism [5, 6] . Medical treatment of moderate-to-severe and active GO is a challenge, and results are frequently unsatisfactory for the patient [7] . Intravenous glucocorticoids (ivGCs) represent the first-line treatment for these forms [8] , and are most commonly given as a course of 12-weekly infusions with a cumulative dose of 4.5 g of methylprednisolone [9] . Higher cumulative doses should be reserved for more severe forms within the moderate-to-severe GO spectrum, because they are more effective but also more often associated with side effects/adverse events [8] . In any case, the cumulative dose should not exceed 8 g [8] . Adverse events related to ivGC treatment are not rare and may be severe [10, 11] , even using the recommended regimens. Therefore, a balance between potential harms and benefits of treatment should be observed, considering that this can change during the course of treatment because of the occurrence of adverse events and/or the lack of response.
In clinical practice patients may respond to ivGCs early or late during the course of treatment, while some are refractory or worsen despite treatment. Clinicians treating such cases are sometimes faced with a dilemma, when halfway through the course of treatment the response is disappointing. Current European guidelines recommend that, when side effects outweigh benefits, withdrawal of ivGC treatment in favor of another modality or watchful monitoring should be considered [8] . It is unknown whether the 6-week assessment of patients during a course of ivGCs predicts the outcome at 12 and 24 weeks. In this study, we took advantage of the largest available database of patients with moderate-to-severe and active GO treated with ivGCs [10] to carry out a post hoc analysis aimed at addressing this issue.
Materials and methods

Patients
Patients included in this study were the 159 participants enrolled in a randomized clinical trial performed by EUGOGO and published in the Journal of Clinical Endocrinology and Metabolism in 2012, in which the efficacy and safety of three different cumulative doses of iv methylprednisolone (2.25, 4.98, or 7.47 g) on moderate-to-severe and active GO were evaluated [10] . Details on study design, baseline characteristics of patients and patients' assessments can be found in the previous publication [10] . Criteria for evaluation of outcomes of treatment ("Improved", "Unchanged", "Deteriorated") are illustrated in Table 1 . The original study was approved by the institutional review boards of participating centers, and informed consent was obtained from all participants.
Statistical analysis
We summarized major demographic and clinical characteristics at baseline of the study participants as sample mean and standard deviation, or prevalence for continuous and discrete variables, respectively. Summary statistics were produced according to response status at week 6, classified as "Improved", "Unchanged" and "Deteriorated" as described in the "Methods". Considering, as end-points, Composite Index (CI), Clinical Activity Score (CAS), and Quality of Life (QoL),we estimated the relative risk (with 95% confidence intervals) of no response at week 12 with respect to baseline according to improvement status at week 6 from Poisson regression models including age, sex and treatment dose as covariates (reference category: patients improved at week 6). Since there were only eight patients with a deteriorated CI at week 6, and none improved at week 12, for this endpoint the Relative Risk was estimated for those with response status "unchanged". These analyses were repeated stratifying by treatment dose. The models for the stratified analyses also included the interaction between response status at week 6 and the stratification variable; the null hypothesis of no effect difference across strata was tested using Wald Chi-square tests.
All the statistical analyses were conducted using the SAS software version 9.4 (Copyright (c) 2002-2012 by SAS Institute Inc., Cary, NC, USA). Statistical analysis was carried out by Giovanni Veronesi.
Results
All the results were expressed as changes, compared to baseline, at 6 weeks and at the end of intervention (12 weeks) and follow-up (24 weeks).
Composite index
As illustrated in Fig. 1, 8 out of 159 patients had a progression of CI at 6 weeks compared to baseline, and were defined as deteriorated at 12 weeks and (with one exception) at 24 weeks. Among the 51 patients whose CI improved at 6 weeks, 65% remained in the improved category at 12 weeks, and 53% at 24 weeks. About onethird were classified as unchanged at 12 and 24 weeks, and 12% were in the "deteriorated" category at 24 weeks, representing relapse of GO after the end of intervention. Onehundred patients were in the "unchanged" category at 6 weeks. Conversion to the "improved" category occurred in 28 and 35% of these patients at 12 and 24 weeks, respectively, although deterioration was observed in 7 and 13%, respectively (Fig. 1) .
Quality of life
As illustrated in Fig. 2 , 48 patients were in the "deteriorated" category at 6 weeks: of them, 25 and 32% moved to the "improved" category at 12 and 24 weeks, respectively. The large majority of patients who improved at 6 weeks remained in the "improved" category at 12 and 24 weeks, but some of them shifted to the "deteriorated" category (Fig. 2) . Both deterioration and improvement of QoL was observed in the "unchanged" patients at 6 weeks when they were reassessed at 12 and 24 weeks, but almost half of these patients (47%) had indeed an amelioration of QoL at the end of follow-up (Fig. 2) .
Clinical activity score
No patient had a deterioration of the CAS at 6 weeks. Among the 69 patients whose CAS was unchanged compared to baseline, 58 and 53% moved to the "improved" category at 12 and 24 weeks, respectively (Fig. 3) . Conversely, among patients whose CAS had improved at 6 months, 13 and 25% moved back to the "unchanged" category at 12 and 24 weeks, respectively (Fig. 3) . Lack of response at week 12 according to patient status at week 6
As illustrated in Table 2 , after adjustment for age, sex, and dose, as compared to improved patients at week 6, the relative risk of no response at week 12 for "unchanged" patients at week 6 was 1.92 for CI, 2.81 for CAS, 4.25 for QoL. These figures indicate that, respectively, "unchanged" patients had 92%, almost threefold and more than fourfold higher risk of no response at week 12, as compared to early "improved" patients, than early improved patients had to remain in this category.
There was a trend for "unchanged" patients at week 6 treated with higher doses towards reaching the same probability of improvement at week 12 than early improved patients had, particularly for CAS and QoL. This is illustrated in Fig. 4 , with relative risks getting closer to 1 as the cumulative dose increased, without reaching statistical significance.
Discussion
IvGCs, the first-line treatment for moderate-to-severe and active GO [6] , are often highly effective in improving the severity and activity of GO, but are not devoid of side effects, which sometimes can be severe [11, 12] . Following the first few infusions of ivGCs clinicians would need to appraise the merits of continuing treatment against the risks of serious side effects. Knowledge of the probability of response at completion of treatment and beyond, based on the early individual patient experience and response, can be extremely useful in decision-making and may limit potential morbidity. This may be particularly valuable in patients, who, following the initial infusions have not manifested any substantial change in their disease severity or activity. Information on the value of an early (or relatively early) response in predicting the final outcome is scanty, although a few studies suggested that an early response may be predictive of a favorable outcome of treatment [13, 14] , while a lack of early response may be associated with little chances (about 10%) of further improvement, assessed by a decrease in the CAS, at the end of treatment [14] .
We believe that the results of this study provide valuable new information. It is evident that patients whose GO deteriorates at 6 weeks in terms of CI, i.e., of the overall ophthalmic involvement, have little/no chance to improve at the end of intervention or during follow-up. However, they may have some improvement in the CAS (inactivation of GO) and QoL, which is probably due to improved inflammation. In these patients, it seems preferable to withdraw ivGCs, unless the purpose of continuing therapy is to eventually inactivate GO and submit the patient to rehabilitative surgery at an earlier stage. This leaves the question of what second-line treatment should be applied to these patients. The recent European Thyroid Association/ EUGOGO guidelines underscored that there is no evidence on the optimal treatment in the clinical setting of no/partial response to intravenous glucocorticoids [8] . This is even less so in the context of a deterioration during ivGC treatment. A possible option is represented by a second course (or continuation) of ivGCs, although it seems unlikely that, if a deterioration occurred, continuing ivGCs be beneficial. Alternatively, oral glucocorticoids combined with orbital radiotherapy [15, 16] or cyclosporine A [17, 18] , or rituximab [19] might be used. Because of the lack of evidence, a shared decision-making process is appropriate to explore thoroughly with the patient the possible harms and benefits of the different treatment modalities [8] .
In patients who at 6 weeks have improved, it seems obvious, unless there are major side effects of or intolerance to treatment, to continue ivGCs until its completion, although it is possible that disease may flare up after withdrawing therapy [10] .
Most interesting is the group of patients whose GO is unchanged at halfway through the course of treatment, as this scenario poses the significant dilemma of whether to continue or stop ivGC therapy. Our results indicate that the absence of an early (or relatively early) response does not exclude the possibility that response to treatment may occur later. The latter might also reflect the natural history of GO. According to our data, patients unresponsive at 6 weeks have about a 30% chance of later amelioration in the overall ophthalmic involvement, about a 60% chance of inactivation of GO, and more than a 30% chance of an improvement in QoL. Although a trend was noted for an association between the cumulative dose of ivGC and conversion from "unchanged" at 6 weeks to "improved" at 12 or 24 weeks, this failed to reach statistical significance. Therefore, it can be concluded that the possible amelioration of GO occurring later during treatment, is independent of the treatment dose. Furthermore, it is worth recalling that the highest cumulative dose of iv methylprednisolone (about 7.5 g) is associated with a higher incidence of adverse events [8] . Based on the above considerations, we do not support the idea that in patients unresponsive at 6 weeks, the weekly dose (and, consequently, the cumulative dose) should be further increased, because not only the cumulative dose, but also the single weekly dose is associated with a higher risk of adverse events, including major adverse events [11, 20] .
Thus, patients unresponsive at 6 weeks still have a significant possibility of improvement later. Accordingly, they may continue ivGC treatment, if well tolerated, or, alternatively, possibly stop ivGCs and be switched to a secondline treatment (Fig. 5) . As discussed above, the therapeutic plan should result from a shared decision-making process that involves an informed patient on pros and cons of continuing versus withdrawing ivGCs, as well as of secondline treatments or watchful waiting.
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